Mainz Biomed and OncoVanguard8 Partner to Introduce ColoAlert in South America
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Collaboration Announcement: Mainz Biomed has signed a Memorandum of Understanding (MOU) with OncoVanguard8, a distributor focused on oncological innovations.
Product Introduction: The partnership aims to launch ColoAlert, a DNA-based colorectal cancer screening test, in South America, beginning with Peru.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
